SCHEMBL2271588

SCHEMBL2271588

O=C(Nc1cc(Oc2ccccc2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.64
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
TDP1 Q9NUW8 2/20 0.62
PKM P14618 2/20 0.62
PYGL P06737 1/20 0.62
PYGM P11217 1/20 0.62
MAPT P10636 1/20 0.62
GRIK1 P39086 1/20 0.62
PGR P06401 2/20 0.60
HPSE Q9Y251 1/20 0.59
NR1H4 Q96RI1 2/20 0.58
GALK1 P51570 1/20 0.56
CASP6 P55212 1/20 0.56
MCL1 Q07820 1/20 0.56
PLEC Q15149 1/20 0.56
POLB P06746 1/20 0.56
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274898 0.93 SERPINE1 (0.60) SERPINE1MEN1KMT2ATDP1PKM
SCHEMBL2276745 0.92 SERPINE1 (0.65) SERPINE1MEN1KMT2ATDP1PYGL
SCHEMBL2273044 0.92 CYP2C9 (0.61) SERPINE1MEN1KMT2ATDP1PKM
SCHEMBL2270621 0.92 GALK1 (0.68) SERPINE1TDP1PYGLPYGMHPSE
SCHEMBL2272706 0.92 MEN1 (0.67) SERPINE1MEN1KMT2ATDP1PKM
SCHEMBL2272347 0.92 SERPINE1 (0.69) SERPINE1MEN1KMT2ATDP1PKM
SCHEMBL2274811 0.92 PYGM (0.57) SERPINE1MEN1KMT2ATDP1PKM
SCHEMBL2272043 0.91 SERPINE1 (0.75) SERPINE1MEN1KMT2ATDP1PKM
SCHEMBL2275467 0.91 CYP2C9 (0.63) SERPINE1MEN1KMT2ATDP1PKM
SCHEMBL2271007 0.91 MEN1 (0.69) SERPINE1MEN1KMT2APKMPYGM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SERPINE1 101/4885MEN1 3105/4885KMT2A 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.